文献速递浆细胞疾病

CXXC1依赖的IRF4活性促进骨髓瘤细胞适应性并维持来那度胺耐药

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance.
PubMed 文献 · Blood · 2026-09-02

本研究探讨CXXC1在骨髓瘤IKZF1/3-IRF4-MYC调控环路中的作用。高CXXC1表达与高危增殖性不良预后相关,CXXC1为骨髓瘤依赖基因并调控细胞适应性程序。CXXC1与IRF4和IKZF3广泛共结合染色质,其缺失导致IRF4和IKZF3染色质结合丢失并破坏IRF4自我调控环路,在来那度胺敏感和耐药细胞中均如此。

要点

  • 高CXXC1表达与骨髓瘤高危增殖性不良预后相关
  • CXXC1是骨髓瘤依赖基因,调控细胞周期、MYC靶点和DNA损伤反应
  • CXXC1缺失破坏IRF4自我调控环路,在来那度胺敏感和耐药细胞中均有效

核心结论

  • CXXC1通过调控IRF4和IKZF3染色质结合及IRF4自我调控环路,维持骨髓瘤细胞适应性,是IMiD敏感和耐药骨髓瘤的潜在治疗靶点。

研究设计与样本

  • 研究利用degron标签CXXC1急性耗竭、原代骨髓瘤细胞染色质可及性分析及CXXC1与IRF4/IKZF3共结合染色质分析,在来那度胺敏感和耐药骨髓瘤细胞中验证CXXC1功能。

主要发现

  • 高CXXC1表达与高危增殖性不良预后疾病相关,CXXC1为骨髓瘤依赖基因并调控细胞周期、MYC靶点和DNA损伤反应。
  • 原代骨髓瘤细胞中高CXXC1表达与更高染色质可及性相关,degron标签CXXC1急性耗竭验证其调控骨髓瘤细胞适应性程序和高危转录特征。
  • CXXC1与IRF4和IKZF3相互作用并广泛共结合染色质,在来那度胺敏感和耐药细胞中CXXC1耗竭导致IRF4和IKZF3染色质结合丢失并破坏IRF4转录自我调控环路。

临床怎么用

  • CXXC1和COMPASS可作为IMiD敏感和耐药骨髓瘤的新治疗靶点,通过调控IRF4活性和骨髓瘤细胞适应性程序发挥作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Regulation of oncogenic transcriptional programs in multiple myeloma requires the interplay of histone modifications, their writers and readers with lineage-affiliated transcription factors. The transcription factors IKZF1/3, IRF4 and MYC form an aberrant, myeloma-specific regulatory loop that drives myelomagenesis and resistance to immunomodulatory drugs (IMiDs) such as lenalidomide. Chromatin-based mechanisms that regulate these processes remain incompletely understood. Here we investigate the role of CXXC1, a core component of the H3K4 methyltransferase complex COMPASS, in the activity of the IKZF1/3-IRF4-MYC regulatory loop. We find that clinically, high CXXC1 expression is associated with high-risk proliferative, adverse prognosis disease. Consistent with this, CXXC1 is a myeloma dependency and it regulates cellular fitness programs including cell cycle, MYC targets and DNA damage response. High CXXC1 expression in primary myeloma cells is associated with higher chromatin accessibility, while acute depletion of degron-tagged CXXC1 further validates its role in regulating myeloma cell fitness programs and high-risk transcriptional signatures. CXXC1 interacts with and extensively co-binds to chromatin with IRF4 and IKZF3. Notably, in both lenalidomide-sensitive and -resistant myeloma cells, CXXC1 depletion results in loss of IRF4 and IKZF3 chromatin binding and in parallel it 'breaks' the IRF4 transcriptional self-regulatory loop. Thus, CXXC1 and COMPASS emerge as novel therapeutic targets in IMiD-sensitive and -resistant myeloma by regulating the activity of IRF4 and essential myeloma cell fitness programs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sabbattini PMR, Trasanidis N, Taslim J, et al. CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance. Blood. 2026. PMID: 42685001. doi:10.1182/blood.2026033534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。